SN5
SHORT NOTE
5M
★ High-yield
Describe theophylline with its mechanism, interactions, toxicity and place in therapy.
Pharmacology
Theophylline is a methylxanthine bronchodilator with a narrow therapeutic index; aminophylline is its more soluble complex with ethylenediamine, used intravenously.
- Mechanisms — (1) adenosine receptor antagonism (adenosine is a bronchoconstrictor and mediates several of the toxic effects, including seizures and arrhythmia); (2) phosphodiesterase inhibition, raising cAMP; and (3) at low doses, activation of histone deacetylase, giving an anti-inflammatory effect and restoring steroid sensitivity
- Actions — bronchodilatation; increased diaphragmatic contractility (useful in COPD); CNS stimulation; cardiac stimulation; diuresis; increased gastric acid secretion
- Therapeutic range 10 to 20 mg/L, and toxicity may begin within it; metabolised by CYP1A2
CLINICAL PEARL
Levels rise when a smoker is admitted to hospital and stops smoking, and this catches people out. Tobacco smoke is a strong CYP1A2 inducer, so a smoker needs a higher theophylline dose. Stop smoking — on admission, in an intensive care unit, or after a successful quit attempt — and induction wanes over about a week while the dose stays the same. The result is toxicity in a patient who has changed nothing except a habit nobody recorded.
Interactions
| Effect on level | Cause |
|---|---|
| Raised (risk of toxicity) | Ciprofloxacin, erythromycin and clarithromycin, cimetidine, allopurinol, fluvoxamine, oral contraceptives, verapamil, propranolol; cardiac failure, liver disease, viral infection, old age |
| Lowered (risk of failure) | Smoking (including cannabis), rifampicin, phenytoin, carbamazepine, phenobarbitone, chronic alcohol; childhood |
Toxicity
- Early — nausea, vomiting, abdominal pain, headache, insomnia, restlessness, tremor
- Serious — tachyarrhythmias (including supraventricular and ventricular tachycardia), seizures which are often refractory, hypokalaemia, hyperglycaemia, metabolic acidosis, hypotension and rhabdomyolysis
- Seizures and arrhythmia may occur without preceding gastrointestinal warning in chronic overdose, particularly in the elderly — so a normal symptom profile does not exclude a dangerous level
- Management — stop the drug; activated charcoal (repeated doses enhance elimination, since theophylline undergoes enteroenteric recirculation); correct potassium; benzodiazepines for seizures; beta-blockers for arrhythmia (cautiously in asthmatics); and haemodialysis or charcoal haemoperfusion in severe poisoning, since it has a small volume of distribution and low protein binding
Place in Therapy
- Now a later-line option in asthma and COPD, after inhaled corticosteroids, LABAs and LAMAs, because of its narrow index and interactions
- Retains a role where cost matters — it is very cheap and orally active, which keeps it in wide use in India, particularly in sustained-release form
- Intravenous aminophylline in acute severe asthma unresponsive to nebulised therapy, with cardiac monitoring; a loading dose is omitted if the patient is already on oral theophylline
- Other uses — neonatal apnoea (where caffeine, a related methylxanthine, is now preferred and is safer)
Applied Aspects
- Measure levels when starting, after any dose change, and whenever an interacting drug is added or stopped — theophylline is one of the few drugs where therapeutic monitoring genuinely changes management
- Ask about smoking status at every review, and reduce the dose when a patient stops
- Check before adding ciprofloxacin or a macrolide to a patient on theophylline; this combination is a classic and entirely avoidable cause of seizures
- Do not give a loading dose without knowing the current level in someone already taking it
- Sustained-release preparations are not interchangeable between brands, and switching can alter levels significantly
- Where inhaled therapy is unaffordable or unavailable, theophylline remains a reasonable option — but it demands the monitoring and interaction vigilance that a safer inhaled drug does not
All questions in Gastrointestinal & Respiratory Drugs
- Q1Describe the physiology of gastric acid secretion. Classify the drugs used in peptic ulcer and reflux disease with their uses and adverse effects. ★
- Q2Describe the physiology of vomiting. Classify antiemetics and describe the choice of drug in different situations. ★
- Q3Classify laxatives and antidiarrhoeal drugs. Describe the drugs used in inflammatory bowel disease. ★
- Q4Classify the drugs used in bronchial asthma. Describe the stepwise management of chronic asthma and of acute severe asthma. ★
- Q5Describe the drugs used in COPD and cough. Describe the methylxanthines with their interactions and toxicity. ★
- SN1Describe the proton pump inhibitors with their mechanism, uses and adverse effects. ★
- SN2Describe the regimens used for Helicobacter pylori eradication and the principles of testing. ★
- SN3Describe the antiemetics used in chemotherapy-induced nausea and vomiting. ★
- SN4Describe the scientific basis, composition and use of oral rehydration therapy. ★
- SN5Describe theophylline with its mechanism, interactions, toxicity and place in therapy. ★
- SN6Describe the inhalational devices and the inhaled corticosteroids. ★
- SN7Describe the drugs used in hepatic encephalopathy and the principles of prescribing in chronic liver disease.